Dose response of ACE inhibitors: implications of the SECURE trial
The choice of the appropriate dosage of ACE inhibitor in clinical practice is an important one. The available evidence suggests that in chronic heart failure as well as in chronic coronary artery disease, high doses of angiotensin-converting enzyme (ACE) inhibitor are more effective than low ones. The current recommended clinical approach is to target ACE inhibitor dosing regimens to be similar to those used in the clinical trials, which demonstrated mortality and morbidity benefits. When titrated appropriately, ACE inhibitors are generally well tolerated and target doses can be achieved and maintained in the majority of patients with atherosclerotic vascular disease, with or without heart failure.
Find Related Datasets
Search by Tags
Click any tag below to search for similar datasets
Complete Metadata
| @type | dcat:Dataset |
|---|---|
| accessLevel | public |
| bureauCode |
[ "009:25" ] |
| contactPoint |
{ "fn": "NIH", "@type": "vcard:Contact", "hasEmail": "mailto:info@nih.gov" } |
| description | The choice of the appropriate dosage of ACE inhibitor in clinical practice is an important one. The available evidence suggests that in chronic heart failure as well as in chronic coronary artery disease, high doses of angiotensin-converting enzyme (ACE) inhibitor are more effective than low ones. The current recommended clinical approach is to target ACE inhibitor dosing regimens to be similar to those used in the clinical trials, which demonstrated mortality and morbidity benefits. When titrated appropriately, ACE inhibitors are generally well tolerated and target doses can be achieved and maintained in the majority of patients with atherosclerotic vascular disease, with or without heart failure. |
| distribution |
[ { "@type": "dcat:Distribution", "title": "Official Government Data Source", "mediaType": "text/html", "description": "Visit the original government dataset for complete information, documentation, and data access.", "downloadURL": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC59639/" } ] |
| identifier | https://healthdata.gov/api/views/iyst-v33z |
| issued | 2025-07-14 |
| keyword |
[ "ace-inhibitors", "coronary-disease", "dose-response", "heart-failure", "nih" ] |
| landingPage | https://healthdata.gov/d/iyst-v33z |
| modified | 2025-09-06 |
| programCode |
[ "009:032" ] |
| publisher |
{ "name": "National Institutes of Health", "@type": "org:Organization" } |
| theme |
[ "NIH" ] |
| title | Dose response of ACE inhibitors: implications of the SECURE trial |
